Genetic Heterogeneity in Bartter Syndrome: Clinical and Practical Importance

Abstract

Bartter syndrome (BS) is a rare tubulopathy that causes polyuria, hypokalemia, hypochloremic metabolic alkalosis, and normotensive hyperreninemic hyperaldosteronism. It is characterized by locus, clinical, and allelic heterogeneity. Types 1–4 of BS are inherited according to an autosomal recessive pattern, while type 5, which is transient, is X linked. There are specific correlations between the clinical expression and the molecular defect, but since it is a rare disease, such studies are rare. Therapeutic interventions are different, being correlated with types of BS.

Introduction

Bartter syndrome (BS) is a rare tubulopathy characterized by polyuria, hypokalemia, hypochloremic metabolic alkalosis, and normotensive hyperreninemic hyperaldosteronism (1). Incidence is 0.1/100,000 (2).

The main mechanism is the defective reabsorption of salt, mainly at the thick ascending limb (TAL) of the loop of Henle (3). TAL intervenes in the homeostasis of extracellular fluid by sodium reabsorption; homeostasis of calcium, magnesium, bicarbonate, and ammonium; and synthesis of uromodulin (Tamm-Horsfall protein) with a role in maintaining the composition of urinary proteins (4).

Hereditary diseases involving proteins of the TAL are classified into three categories according to the TAL function affected: sodium reabsorption, calcium and magnesium reabsorption, and uromodulin synthesis. The first category includes BS types 1–5 and HELIX syndrome (hypohidrosis, electrolyte imbalance, lacrimal gland dysfunction, ichthyosis, and xerostomia) (produced by mutations in CLDN10 gene). The second category includes familial hypomagnesemia with hypercalciuria and nephrocalcinosis (produced by mutations in CLDN16 or CLDN19 genes), familial hypercalcemia hypocalciuric types 1–3 (produced by mutations in CASR, GNA11, AP2S1 genes), and autosomal dominant hypocalcemia types 1–2 (produced by mutations in CASR, GNA11 genes). Hyperuricemic nephropathy, familial juvenile 1 (produced by UMOD gene) belongs to the third category (4).

Genes and Proteins in Bartter Syndrome

Bartter syndrome is caused by mutations in genes encoding K⁺ channel (KCNJ1 gene), Cl^– channel (CLCNKA and CLCNKB genes), their cotransporters (SLC12A1 gene), subunits of these channels (BSND gene), or regulators of the expression of certain transport channels (MAGE-D2 gene).

Table 1 summarizes the genes implied in the pathogeny of various types of BS. Figure 1 describes the gene expressions in different segments of the nephron and correspondent type of the BS.

FIGURE 1

Pathophysiology

At the descending limb of the loop of Henle, the urine becomes more and more hypertonic because this segment is permeable to water that passes extraluminal (passive transport) (8). At the level of the thin segment of the ascending limb, NaCl is reabsorbed according to the laws of osmosis. At the thick segment of the ascending limb and distal convoluted tubules (initial segment), Cl^–, Na⁺, and K⁺ are actively reabsorbed (Figure 2). The result is a hypotonic urine. The collecting duct level is permeable to urea and water, and finally urine becomes hypertonic. These final changes at the nephron level are controlled by the antidiuretic hormone (ADH) that acts on the terminal segment of the distal tube and on the collecting duct (1). An important role in its regulation is played by the juxtaglomerular apparatus (JGA) which mediates the tubuloglomerular feedback (TGF). Under normal conditions, a decrease of intracellular concentration of Cl^– in JGA cells indicates a reduced filtration which determines an activation of TGF, with the stimulation of renin synthesis and hyperfiltration. In patients with BS, TGF is uncoupled because Cl^– is not reabsorbed into the macula densa. The cyclooxygenases are activated and large amounts of prostaglandin E2 are synthesized regardless of volume status, and this produces an excess of renin and aldosterone (1, 9).

FIGURE 2

Hypovolemia activates the renin-aldosterone system, with elevation of renin and aldosterone levels in blood and urine (10). The effects of aldosterone on the distal tubule are as follows: the increase of Na⁺ reabsorption from the lumen in exchange with K⁺ and the stimulation of exchange between the intracellular H⁺ and the intraluminal K⁺. In the first case, Na⁺/K⁺-ATPase pumps increase the intracellular K⁺ which results in an increase in the gradient with respect to the lumen. In this way, K⁺ will leave the cell in the lumen and in the urine (10). In the second case, metabolic alkalosis increases due to the loss of H⁺ in urine (10).

Thick ascending limb cells are responsible for 25–30% of the reabsorbed NaCl in the kidneys (4, 11).

The segments of the Henle loop (proximal straight tubule, thin descending, thin ascending limb, and TAL) are differentiated by the thickness of the walls and the properties of the epithelium. The descending and ascending segments are placed in the renal medulla, while the TAL is located distally. In the kidney medulla, the Na⁺/K⁺-ATPase has low levels and low transport activity. There are also differences between different cells and segments in terms of Na⁺/K⁺-ATPase activity, SLC12A1 splicing, and phosphorylation (11).

SLC12A1

SLC12A1 is the major renal sodium, potassium, and chloride ion cotransporter expressed on the luminal membrane of renal epithelial cells of the TAL and macula densa. Its physiological functions are urine concentration, regulation of Ca²⁺ excretion, and reabsorption of NaCl in TAL (12). It is responsible for most of the NaCl absorption (6, 7).

All 12 solute carrier family proteins have some common properties: transport-coupled one cation per each transported anion (in the case of SLC12A1, for each one K⁺ and one Na⁺ that leave the cell enter two Cl^–) which determines an electric balance; the anion is always the chlorine ion; their activity is modified by the changes in the cell volume; and the intracellular concentration of the chlorine ion; activity regulation is done by phosphorylation and dephosphorylation (12). It is positively regulated by WNK3 serine/threonine-protein kinase that activates SLC12A1 by phosphorylation and inhibits by dephosphorylation (12). This action is mediated by cation-chloride cotransporters (CCCs) dependent on cell tonicity (13). A decreased cell volume leads to phosphorylation of cotransporters by Serine/threonine-protein kinase STE20 (12, 14, 15).

Three full-length SLC12A1 isoforms exist in humans: isoform A, isoform B, and isoform F. Isoform A is the most intensely expressed (16, 17). However, there are differences in gene expression between different segments of TAL: isoforms A and F are mostly expressed in the outer stripe of the outer medulla, while isoform B is active in the cortex (16, 17). In addition, the affinity for Cl^– of isoforms decreases in this order: isoform B, isoform F, and isoform A, a feature concordant with spatial localization of these isoforms. Thus, the isoforms with higher affinity are expressed in C-TAL where there is a higher concentration of Cl^–, while in M-TAL, the lower-affinity isoforms are present and concordant with low levels of Cl^– (16, 17).

CIC-K

ClC-Ka and ClC-Kb are expressed differently in the epithelial cells of the nephron, inner ear, and salivary glands (18). The ClC-K channels have the largest protopore conductance values. These values range from 15 to 22 ps (18).

The ClC-K channels inserted in the basolateral membrane of nephron epithelia require a barttin subunit for proper function. Lack of barttin causes BS type 4a with renal loss of NaCl (7). ClC-Kb inactivating mutations cause BS type 3 (7, 17). ClC-Ka is expressed mainly in the thin limb of the Henle loop, while ClC-Kb is expressed in the TAL, distal-convoluted tubules, and in collecting duct-intercalated cells (7, 19). ClC-Ka, ClC-Kb, and barttin are also expressed in the ear where they are involved in the endolymph secretion. Both modified isoforms or their common beta subunit (barttin) cause deafness in BS type 4 (18).

CLCNKA and CLCNKB

CLCNKA and CLCNKB are neighboring genes, present similar sequences, and probably result from the duplication of an ancestral gene. Deletions/non-sense mutations in CLCNKB produce loss of channel function which affects the response of the ClC-Kb complex to pH and Ca²⁺.

ROM-K

ROM-K is an ATP-sensitive channel with low conductance, located at the apical pole of the cells. There is no difference between the expression ROM-K in M-TAL and C-TAL; it is expressed from the inner stripe of the outer medulla to the macula densa (17).

MAGE-D2

MAGE-D2 is a nucleolar protein that increases SLC12A1 expression in the human TAL and in the distal convoluted tubules. MAGE-D2 interacts with HSP40 allowing the protection of proteins. Also, MAGE-D2 in association with Gs-alpha promotes the insertion of SLC12A1 and NCC (NaCl-co-transporter) into the plasma membrane. In Barter type 5, due to the existence of an abnormal MAGE-D2, protein degradation is amplified, associated with low levels of SLC12A1 and NCC (4, 20).

Clinical Signs

The typical symptoms in children with BS are polyhydramnios, premature delivery, polyuria, polydipsia, signs of hypovolemia, failure to thrive, and poor growth (21).

The age of presentation is different according to the type of mutation. For the BS types 4 and 5, polyhydramnios is earlier compared to BS types 1 and 2. The onset of BS type 3 is later in life and only rarely in the antenatal period (22).

There are rare cases of asymptomatic children diagnosed with BS. These cases presented hypokalemia metabolic alkalosis, normal blood pressure, and nephrocalcinosis, and usually such patients are discovered after a screening applied in a family with positive history of BS (23–26).

Antenatal Symptomatology

The most frequent feature is the polyhydramnios detected during pregnancy, starting at 22 weeks of gestation (3). The onset of polyhydramnios is earlier in fetuses with BS types 4 and 5 (BSND or MAGED2 variants) and represent the most severe forms. In BS type 1 (SLC12A1) and BS type 2 (KCNJ1), the onset of polyhydramnios is much tardive, concordant with a lower severity. In BS type 3 (CLCNKB), polyhydramnios is either absent or mild (3, 20).

Antenatal genetic testing and biochemical analysis of amniotic fluid, the concentration of total protein and alpha-fetoprotein (decreased in BS), the Bartter index (which is defined corresponding to the multiplication of total protein and of AFP, both expressed in multiple of median—MoM) with 86% sensitivity and 84% specificity, can be used to confirm the diagnosis (27, 28).

Neonatal Symptomatology

All BS types, except BS type 3, have a neonatal onset with preterm birth (median gestational age between 29 and 33 weeks) and massive polyuria which lead to dehydration and rapid weight loss. Infants with BS type 4 have supplementary sensorineural hearing loss (22, 29).

The diagnosis can be confirmed using a next-generation sequencing (NGS) testing with gene panels that contain SLC12A1, KCNJ1, BSND, CLCNKA, CLCNKB, MAGED2, and SLC12A3 gene. These tests have 75% sensitivity and 90–100% specificity (30).

Childhood Symptomatology

Older infants and young children with BS type 3 fail to thrive, growth retardation, and present polyuria/polydipsia that lead to hypovolemia, persistent thirst, salt craving, constipation, unexplained fever, hypotonia, and recurrent vomiting (23–25).

Teenage Symptomatology

Older children and adolescents with BS type 3 can present thirst, salt craving, fatigue, muscle weakness, cramps, nocturia, constipation, poor growth, and pubertal delay.

In BS type 4, there is a risk for chronic kidney disease (CKD) and end stage renal disease (ESRD) (22).

Bartter syndrome type 5 (transient type) has some extrarenal clinical features: frontal bone cyst, dysmorphic facies, hydrocephalus and Chiari malformation, Marfanoid habitus with arachnodactyly and mitral insufficiency, pyloric stenosis, high blood pressure, interauricular communication, left ventricle hypertrophy, right aortic arch, retroesophageal left subclavian artery, moderate pulmonary stenosis, enteropathic acrodermatitis zinc deficiency type, angioma, thrombocytopenia, and deafness after the age of 2 (3, 4, 31).

The laboratory findings constant in all forms of BS are hypochloremic metabolic alkalosis, elevated renin and aldosterone levels, low to normal blood pressure due to chronic hypovolemia, low urine osmolality due to impaired concentrating ability, and hypokalemia (potassium levels that are less than 3 mmol/L). Transient neonatal hyperkalemia may be present only in patients with BS type 2. Hypercalciuria is present in patients with BS types 1 and 2 (associated with nephrocalcinosis) and also in BS type 5 (the nephrocalcinosis is rare and mild in this type). The normocalciuria is present in patients with BS types 3 and 4, and the hypocalciuria in patients with BS type 3. The mild hypomagnesemia may be present in some patients with BS type 3. Plasma Cl/Na ratio can be normal in BS types 1 and 2, decreased in BS types 3 and 4, and increased in BS type 5 (1, 21, 32–35).

Genetic Testing

Genetic testing is recommended in any clinical suspicion of BS. The European Rare Kidney Disease Reference Network Working Group for Tubular Disorders recommends a gene panel testing. This panel must contain not only all genes that cause BS and Gitelman syndrome but also genes that overlap phenotypically with BS and should be considered in differential diagnosis with BS: SLC12A1, KCNJ1, CLCNKB, CLCNKA, BSND, MAGED2, SLC12A3, CASR, KCNJ10, SLC26A3, CLDN10, SCNN1A, SCNN1B, SCNN1G, NR3C2, HSD11B2, CYP11B1, CLCN2, KCNJ5, and CACNA1H (1). Genetic testing is required for several reasons: confirmation of clinical diagnosis, adequate genetic counseling, adequate management of diseases with overlapping phenotypes, screening for deafness in BS type 4, and avoidance of aggressive treatment in transient BS type 5 (1).

Mutational heterogeneity is important in BS. According to the Human Gene Mutation Database Professional HGMD Professional 2021.4 (accessed in February 2022), 350 pathogenic variants were described. Figure 3 shows the implication in BS of different types of genetic modifications. The most common was missense/non-sense mutation, splicing substitution, small deletions, and gross deletion especially in SLC12A1, CLCNKB, and KCNJ1 genes.

FIGURE 3

Differential Diagnosis

The differential diagnosis of BS should be made with conditions where the main signs are poyhydramnios, salt loss, salt loss with hypokalemic alkalosis, hypokalemic alkalosis without salt loss, and nephrocalcinosis (1, 22).

The polyhydramnios may be a sign present in aneuploidia (the karyotype is abnormal), different gastrointestinal malformations, and congenital chloride diarrhea (dilated intestinal loops present).

The salt loss can be a manifestation in pseudohypoaldosteronism type I, but in this case is associated with metabolic acidosis and hyperkalemia.

The salt loss with hypokalemic alkalosis can be a sign in congenital chloride diarrhea, pseudo-BS (in cystic fibrosis, for example), surreptitious vomiting, surreptitious laxative use (in these entities, the additional finding is low urinary chloride), Gitelman syndrome (associated hypocalciuria and hypomagnesemia), HNF1B (hepatocyte nuclear factor 1 beta), nephropathy (associates renal malformation, MODY5—maturity onset diabetes of the young type 5, hypomagnesemia), HELIX syndrome (hypercalcemia is present), autosomal dominant hypocalcemia, EAST/SeSAME syndrome (seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance), and surreptitious diuretic use (1, 22).

Hypokalemic alkalosis without salt loss associated hypertension with low renin/aldosterone and can be found in primary hyperaldosteronism, apparent mineralocorticoid excess, and Liddle syndrome (1, 22).

The nephrocalcinosis can also be found in distal renal tubular acidosis (metabolic acidosis), medical conditions without metabolic alkalosis (proximal tubular defects, familial hypomagnesemia/hypercalciuria), and apparent mineralocorticoid excess (1, 22).

Therapy of Bartter Syndrome

The antenatal therapy consists of repeated amniocentesis and/or maternal administration of NSAID (non-steroidal anti-inflammatory drug) in order to reduce the amniotic fluid volume. There are potential risks for the fetus (such as necrotizing enterocolitis or premature closure of the ductus arteriosus). The evidence is not sufficient to show that the benefit outweighs the potential adverse effects (1). The main therapeutic interventions are summarized in Table 2.

The postnatal therapy consists of maximal caloric intake in order to facilitate optimal growth (1), fluid repletion, sodium chloride (NaCl) supplementation of at least 5–10 mEq/kg/d, and potassium chloride (KCl) 1–2 mEq/d, spread out in frequent doses throughout the day, in order to compensate the urinary losses (1, 37).

Non-steroidal anti-inflammatory drugs that inhibit prostaglandin E2, which contributes to high urinary NaCl losses, are recommended in case of inadequate response in symptomatic patients with BS, especially in early childhood (38). Oral magnesium supplementation is recommended in case of hypomagnesemia [<1.70 mg/dl (0.7 mmol/L)] (37, 39). In case of symptomatic hypokalemia despite the supplements, potassium-sparing diuretics (such as spironolactone, eplerenone, or amiloride), angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers can be used (1, 37).

Follow-Up in Bartter Syndrome

The patients with BS should be followed in pediatric or adult centers experienced in tubular disorders. The recommended frequency of hospital visits is 3–6 months for infants and young children and 6–12 months for adults. All the recommendations are summarized in Table 3. A clinical work on hydration status, degree of polyuria, muscular weakness, growth, and psychomotor development is recommended at each follow-up visit (1, 22).

A biochemical work focused on metabolic acid-base status (either blood gas or by measurement of venous total CO₂), serum electrolytes (natremia, potassium, chloride, magnesium, and bicarbonate levels), renal function, microalbuminuria, urinary calcium excretion, PTH, and urine osmolality for the detection of nephrogenic diabetes insipidus is recommended at each follow-up visit (1, 22).

Growth hormone deficiency may be considered for children with growth retardation despite treatment.

Renal ultrasound is recommended to be performed at least every 12–24 months to monitor the occurrence of kidney stones, nephrocalcinosis, and obstructive uropathy.

Cardiac work out is recommended for patients (particularly adults) with palpitations or syncope. The physician can use the drugs that slow the sinus rhythm (beta-blockers, calcium channel blockers as verapamil, diltiazem, digoxin) or drugs that influence the QT interval (proton pump inhibitors, fluoroquinolones, macrolides, gentamicin, or antiviral drugs). Electrocardiography, Holter, and stress electrocardiography are recommended to detect cardiac arrhythmias which are determined by a prolonged QT interval in the context of hypokalemia and hypomagnesemia (1, 22).

The quality of life is important to be assessed by using age-specific standardized questionnaires. The quality-of-life scores are related by biochemical parameters (potassium and aldosterone) (1, 41).

Sports can be performed with a good hydration and additional salt and electrolytes.

Anesthesia for patients with BS must be performed after improvement of hypokalemia and hypomagnesemia, which in addition with anesthetic agents can lead to neuromuscular blockage. Potassium levels > 3.0 mmol/L and magnesium > 0.5 mmol/are suggested by guidelines (42).

Kidney Disease

Renal disease is characterized by urolithiasis, obstructive uropathy, and nephrocalcinosis. Nephrotic-range proteinuria has also been reported in patients with BS (21, 24, 43). Renal biopsy can show diffuse glomerular and tubule-interstitial lesions with enlarged glomeruli and focal segmental glomerulosclerosis (23).

Only some patients have an evolution to end-stage kidney disease. CKD can occur as a late manifestation in patients with BS, particularly types 1, 4a, and 4b (21, 23, 44). The CKD in BS seems to have several mechanisms: chronic stimulation of the renin–angiotensin system, periodic dehydration, prematurity, nephrocalcinosis, long-term NSAID drug treatment, and chronic hypokalemia (4).

There are few reported cases of kidney transplants (23, 45–50). The electrolytes and urinary concentrating abnormalities were corrected. No evidence of recurrent disease was observed.

Few studies reported growth failure with growth hormone (GH) deficiency in patients with BS, particularly type 3 who have severe metabolic abnormalities. The poor growth explanation is unclear: acid-base or electrolyte disturbances in BS or whether it is an intrinsic part of the disorder. After metabolic control, recombinant human GH supplementation can be performed (21, 24, 51–53).

Conclusion

Knowledge of clinical heterogeneity in BS is important for initiating genetic investigations and proper management. Early molecular diagnosis is desirable for personalized therapy.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

• 1.

  KonradMNijenhuisTAricetaGBertholet-ThomasACaloLACapassoGet alDiagnosis and management of bartter syndrome: executive summary of the consensus and recommendations from the European rare kidney disease reference network working group for tubular disorders.Kidney Int. (2021) 99:324–35. 10.1016/j.kint.2020.10.035

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 2.

  Orphanet Report Series.«Prevalence of Rare Diseases: Bibliographic Data», Orphanet Report Series, Rare Diseases Collection, Janvier 2022. (2022). Available online at:https://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf(accessed March 15, 2022).

  • Google Scholar

• 3.

  LegrandATreardCRoncelinIDreuxSBertholet-ThomasABrouxFet alPrevalence of novel MAGED2 mutations in antenatal Bartter syndrome.Clin J Am Soc Nephrol. (2018) 13:242–50. 10.2215/CJN.05670517

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 4.

  Vargas-PoussouR. Pathophysiological aspects of the thick ascending limb and novel genetic defects: helix syndrome and transient antenatal Bartter syndrome.Pediatr Nephrol. (2021) 37:239–52. 10.1007/s00467-021-05019-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 5.

  HGNC, HUGO Gene Nomenclature Committee.The Resource for Approved Human Gene Nomenclature. (2022). Available online at:http://www.genenames.org/(accessed March 28, 2022).

  • Google Scholar

• 6.

  UNIPROT.The Mission of UniProt is to Provide the Scientific Community with a Comprehensive, High-Quality and Freely Accessible Resource of Protein Sequence and Functional Information. (2022). Available online at:https://www.uniprot.org/(accessed March 25, 2022).

  • Google Scholar

• 7.

  da Silva CunhaTHeilbergIP. Bartter syndrome: causes, diagnosis, and treatment.Int J Nephrol Renovasc Dis. (2018) 11:291. 10.2147/IJNRD.S155397

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 8.

  CovicMCovicAArdeleanuŞ. Anatomy and physiology of the kidneys. In: CovicAeditor.Nephrology. Theoretical and Practical Principles. (Iasi: Demiurg Press) (2011). p. 21–35.

  • Google Scholar

• 9.

  ReinalterSCJeckNBrochhausenCWatzerBNüsingRMSeyberthHWet alRole of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome.Kidney Int. (2002) 62:253–60. 10.1046/j.1523-1755.2002.00435.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 10.

  AmirlakIDawsonKP. Bartter syndrome: an overview.QJM. (2000) 93:207–15. 10.1093/qjmed/93.4.207

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 11.

  DimkeHSchnermannJ. Axial and cellular heterogeneity in electrolyte transport pathways along the thick ascending limb.Acta Physiol (Oxf). (2018) 223:e13057. 10.1111/apha.13057

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 12.

  de Los HerosPPacheco-AlvarezDGambaG. Role of WNK kinases in the modulation of cell volume.Curr Top Membr. (2018) 81:207–35. 10.1016/bs.ctm.2018.08.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 13.

  GambaG. The thiazide-sensitive Na-Cl cotransporter: molecular biology, functional properties, and regulation by WNKs.Am J Physiol Renal Physiol. (2009) 297:F838–48. 10.1152/ajprenal.00159.2009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 14.

  KahleKTRinehartJGiebischGGambaGHebertSCLiftonRP. A novel protein kinase signaling pathway essential for blood pressure regulation in humans.Trends Endocrinol Metab. (2008) 19:91–5. 10.1016/j.tem.2008.01.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 15.

  DelpireEGagnonKB. SPAK and OSR1: STE20 kinases involved in the regulation of ion homoeostasis and volume control in mammalian cells.Biochem J. (2008) 409:321–31. 10.1042/BJ20071324

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 16.

  CarotaITheiligFOppermannMKongsupholPRosenauerASchreiberRet alLocalization and functional characterization of the human NKCC2 isoforms.Acta Physiol (Oxf). (2010) 199:327–38. 10.1111/j.1748-1716

  • CrossRef
  • Google Scholar

• 17.

  BankirLFigueresLProt-BertoyeCBoubyNCrambertGPrattJHet alMedullary and cortical thick ascending limb: similarities and differences.Am J Physiol Renal Physiol. (2020) 318:F422–42. 10.1152/ajprenal.00261.2019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 18.

  JentschTJPuschM. CLC chloride channels and transporters: structure, function, physiology, and disease.Physiol Rev. (2018) 98:1493–590. 10.1152/physrev.00047.2017

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 19.

  HenningsJCAndriniOPicardNPaulaisMHuebnerAKCayuqueoIKLet alThe ClC-K2 chloride channel is critical for salt handling in the distal nephron.J Am Soc Nephrol. (2017) 28:209–17. 10.1681/ASN.2016010085

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 20.

  LaghmaniKBeckBBYangSSSeaayfanEWenzelAReuschBet alPolyhydramnios, transient antenatal Bartter’s syndrome, and MAGED2 mutations.N Engl J Med. (2016) 374:1853–63. 10.1056/NEJMoa1507629

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 21.

  WalshPRTseYAshtonEIancuDJenkinsLBieniasMet alClinical and diagnostic features of Bartter and Gitelman syndromes.Clin Kidney J. (2018) 11:302–9. 10.1093/ckj/sfx118

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 22.

  KonradMNijenhuisTAricetaGBertholet-ThomasACaloLACapassoGet alDiagnosis and Management of Bartter Syndrome: Consensus and Recommendations from the ERKNet Working Group for Tubular Disorders. (2020). Available online at:https://www.erknet.org/guidelines-pathways/tubulopathies/bartter-syndrome(accessed April 11, 2022).

  • Google Scholar

• 23.

  SeysEAndriniOKeckMMansour-HendiliLCourandPYSimianCet alClinical and genetic spectrum of Bartter syndrome type 3.J Am Soc Nephrol. (2017) 28:2540–52. 10.1681/ASN.2016101057

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 24.

  BettinelliABorsaNBellantuonoRSyrènMLCalabreseREdefontiAet alPatients with biallelic mutations in the chloride channel gene CLCNKB: long-term management and outcome.Am J Kidney Dis. (2007) 49:91–8. 10.1053/j.ajkd.2006.10.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 25.

  KonradMVollmerMLemminkHHVan Den HeuvelLPJeckNVargas-PoussouRet alMutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome.J Am Soc Nephrol. (2000) 11:1449–59. 10.1681/ASN.V1181449

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 26.

  BrochardKBoyerOBlanchardALoiratCNiaudetPMacherMAet alPhenotype–genotype correlation in antenatal and neonatal variants of Bartter syndrome.Nephrol Dial Transplant. (2009) 24:1455–64. 10.1093/ndt/gfn689

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 27.

  AllafBDreuxSSchmitzTCzerkiewiczILe VaillantCBenachiAet alAmniotic fluid biochemistry in isolated polyhydramnios: a series of 464 cases.Prenat Diagn. (2015) 35:1331–5. 10.1002/pd.4700

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 28.

  GarnierADreuxSVargas-PoussouROuryJFBenachiADeschênesGet alBartter syndrome prenatal diagnosis based on amniotic fluid biochemical analysis.Pediatr Res. (2010) 67:300–3. 10.1203/PDR.0b013e3181ca038d

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 29.

  BirkenhägerROttoESchürmannMJVollmerMRufEMMaier-LutzIet alMutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure.Nat Genet. (2001) 29:310–4. 10.1038/ng752

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 30.

  AshtonEJLegrandABenoitVRoncelinIVenisseAZennaroMCet alSimultaneous sequencing of 37 genes identified causative mutations in the majority of children with renal tubulopathies.Kidney Int. (2018) 93:961–7. 10.1016/j.kint.2017.10.016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 31.

  ArthuisCJNizonMKomhoffMBeckBBRiehmerVBihoueeTet alA step towards precision medicine in management of severe transient polyhydramnios: MAGED2 variant.J Obstet Gynaecol. (2018) 39:395–7. 10.1080/01443615.2018.1454415

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 32.

  PetersMJeckNReinalterSLeonhardtATönshoffBünter KlausGet alClinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies.Am J Med. (2002) 112:183–90. 10.1016/S0002-9343(01)01086-5

  • CrossRef
  • Google Scholar

• 33.

  CastropHSchießlIM. Physiology and pathophysiology of the renal Na-K-2Cl cotransporter (NKCC2).Am J Physiol Renal Physiol. (2014) 307:F991. 10.1152/ajprenal.00432.2014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 34.

  OppermannMMizelDKimSMChenLFaulhaber-WalterRHuangYet alRenal function in mice with targeted disruption of the A isoform of the Na-K-2Cl co-transporter.J Am Soc Nephrol. (2007) 18:440–8. 10.1681/ASN.2006091070

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 35.

  OppermannMMizelDHuangGLiCDengCTheiligFet alMacula densa control of renin secretion and preglomerular resistance in mice with selective deletion of the B isoform of the Na. K, 2Cl co-transporter.J Am Soc Nephrol. (2006) 17:2143–52. 10.1681/ASN.2006040384

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 36.

  StensonPDMortMBallEVEvansKHaydenMHeywoodSet alThe human gene mutation database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies.Qual Life Res. (2017) 136:665–77. 10.1007/s00439-017-1779-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 37.

  KömhoffMReinalterSCGröneHJSeyberthHW. Induction of microsomal prostaglandin E2 synthase in the macula densa in children with hypokalemic salt-losing tubulopathies.Pediatr Res. (2004) 55:261. 10.1203/01.PDR.0000101747.09626.6B

  • CrossRef
  • Google Scholar

• 38.

  RanadeVVSombergJC. Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans.Am J Ther. (2001) 8:345. 10.1097/00045391-200109000-00008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 39.

  BlanchardABockenhauerDBolignanoDCaloLACosynsEDevuystOet alGitelman syndrome: consensus and guidance from a kidney disease: improving global outcomes (KDIGO) controversies conference.Kidney Int. (2017) 91:24–33. 10.1016/j.kint.2016.09.046

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 40.

  BockenhauerDvan’T HoffWDattaniMLehnhardtASubtireluMHildebrandtFet alSecondary nephrogenic diabetes insipidus as a complication of inherited renal diseases.Nephron Physiol. (2010) 116:23–9. 10.1159/000320117

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 41.

  EderMDarmannEHallerMCBojicMPeck-RadosavljevicMHuditzRet alMarkers of potassium homeostasis in salt losing tubulopathies—associations with hyperaldosteronism and hypomagnesemia.BMC Nephrol. (2020) 21:256. 10.1186/s12882-020-01905-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 42.

  GallagherHSoarJTomsonC. New guideline for perioperative management of people with inherited salt-wasting alkaloses.Br J Anaesth. (2016) 116:746–9. 10.1093/bja/aew102

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 43.

  PuricelliEBettinelliABorsaNSironiFMattielloCTammaroFet alLong-term follow-up of patients with Bartter syndrome type I and II.Nephrol Dial Transplant. (2010) 25:2976–81. 10.1093/ndt/gfq119

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 44.

  JeckNReinalterSCHenneTMargWMallmannRPaselKet alHypokalemic salt-losing tubulopathy with chronic renal failure and sensorineural deafness.Pediatrics. (2001) 108:E5. 10.1542/peds.108.1.e5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 45.

  BlethenSLvan WykJJLorentzWBJennetteJC. Reversal of Bartter’s syndrome by renal transplantation in a child with focal, segmental glomerular sclerosis.Am J Med Sci. (1985) 289:31–6. 10.1097/00000441-198501000-00006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 46.

  TakahashiMYanagidaNOkanoMIshizakiAMeguroJKukitaKet alA first report: living related kidney transplantation on a patient with Bartter’s syndrome.Transplant Proc. (1996) 28:1588.

  • Pubmed Abstract
  • Google Scholar

• 47.

  KimJYKimGASongJHLeeSWHanJYLeeJSet alA case of living-related kidney transplantation in Bartter’s syndrome.Yonsei Med J. (2000) 41:662–5. 10.3349/ymj.2000.41.5.662

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 48.

  UekiROkutaniRFukushimaATsujiTOhataHTashiroC. Perioperative endocrinological findings in a patient with Bartter’s syndrome and living-related renal transplantation.J Anesth. (2000) 14:105–8. 10.1007/s005400050076

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 49.

  KitanakaSSatoUMaruyamaKIgarashiT. A compound heterozygous mutation in the BSND gene detected in Bartter syndrome type IV.Pediatr Nephrol. (2006) 21:190–3. 10.1007/s00467-005-2091-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 50.

  LeeSEHanKHJungYHLeeHKKangHGMoonKCet alRenal transplantation in a patient with Bartter syndrome and glomerulosclerosis.Korean J Pediatr. (2011) 54:36–9. 10.3345/kjp.2011.54.1.36

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 51.

  AkilIOzenSKandilogluARErsoyB. A patient with Bartter syndrome accompanying severe growth hormone deficiency and focal segmental glomerulosclerosis.Clin Exp Nephrol. (2010) 14:278–82. 10.1007/s10157-009-0262-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 52.

  Gil-PeñaHMejiaNAlvarez-GarciaOLoredoVSantosF. Longitudinal growth in chronic hypokalemic disorders.Pediatr Nephrol. (2010) 25:733–7. 10.1007/s00467-009-1330-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 53.

  BuyukcelikMKeskinMKilicBDKorYBalatA. Bartter syndrome and growth hormone deficiency: three cases.Pediatr Nephrol. (2012) 27:2145–8. 10.1007/s00467-012-2212-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar